BayHelix And Elsevier Business Intelligence Announce Winners Of China Pharma
Awards During PharmAsia Summit Shanghai
SHANGHAI, CHINA -- (Marketwired) -- 10/22/13 -- The BayHelix Group
and Elsevier Business Intelligence (EBI) announced today the winners
of our 2013 China Pharma Awards, which celebrate innovative research
and business models in China.
"This year's winners exemplify how biopharma innovation is evolving
in China across the value chain, from discovery to alliances to
creative commercial models," said Jimmy Zhang, PhD, MBA, chairman of
BayHelix. "Innovative models have become essential to the strategy
and success of both multinationals and leading domestic pharma
The 2013 BayHelix-Elsevier Awards were announced at a ceremony during
the PharmAsia Summit Shanghai, October 22, 2013. Awards winners were
selected by BayHelix and EBI from a list of nominees submitted by
members of the China and global pharmaceutical community.
"The awards celebrate the contribution of innovative leaders in China
as the global industry increasingly recognizes the strategic
importance of China and looks for new models for growth," said Joshua
Berlin, head of emerging markets for EBI.
The 2013 BayHelix-Elsevier Award winners are:
R&D Achievement of the Year recognizes a scientific discovery in
China with direct impact to drug R&D or a significant achievement in
pharmaceutical development milestones.
Shenogen Pharma Group, for the discovery of ER-36 as a novel cancer
target and development of clinical candidate for breast cancer and
Alliance of the Year recognizes a ground breaking pharmaceutical
collaboration agreement involving a Chinese entity.
BeiGene Ltd./Merck KGaA, for a global licensing, co-development and
commercialization agreement for BeiGene-283, a second-generation BRAF
inhibitor for the treatment of cancer.
Commercial Achievement of the Year recognizes a creative model that
delivered superior value to patients/payers in China and commercial
Novartis AG, for Jian Kang Kuai Che (JKKC), or "Health Express," a
social ventures initiative in the Xinjiang region of China.
The fourth PharmAsia Summit, organized by EBI and BayHelix, was held
October 21-23 in Shanghai. The Summit focused on new R&D and
commercial models in a rapidly changing China. During the Summit, top
industry leaders from China and the West discussed new growth models
for China via a series of case studies, panels and keynotes.
For further information, please visit:
About Elsevier Business Intelligence:
Intelligence, a global leader in the field of healthcare industry
information, provides business intelligence on regulatory, business
and reimbursement issues that are vital to the healthcare industry.
Through a range of products including publications, conferences,
e-learning, databases and reports, Elsevier Business Intelligence
places biopharma and medical device professionals, and those who
focus on these industries, at the forefront of knowledge, by
providing the perfect combination of news and information together
with penetrating insight and analysis. Our leading publications
include PharmAsia News, IN VIVO and "The Pink Sheet." For more
information, visit: http://www.ElsevierBi.com.
About BayHelix Group:
BayHelix is an organization of leaders of
Chinese heritage in the global life sciences and healthcare
community. We aspire to shape the growth of the life sciences and
healthcare industry around the Pacific Rim and beyond, foster and
create business opportunities, supply and nurture the leaders for the
community, and network and share information and experience. BayHelix
is a non-profit organization and its membership is
by-invitation-only. For more information, visit:
Elsevier Business Intelligence
Press spacebar to pause and continue. Press esc to stop.